GLP-1药物或可保护脑功能
Obesity drugs could lead to new ways to protect the brain
研究人员评估了GLP-1药物对认知功能的影响,动物研究表明这些药物可能影响记忆和学习,但人类研究结果不一。尽管Novo Nordisk的临床试验EVOKE和EVOKE+未显示semaglutide减缓早期阿尔茨海默病患者的疾病进展,但这些结果并不排除药物在其他患者中保护脑功能的可能性。研究人员呼吁开展更多临床试验以跟踪治疗开始时的认知功能变化。
Drugs such as semaglutide and tirzepatide are already used to treat obesity and type 2 diabetes, but they also influence biological processes important for brain function. In a new review published in Science, researchers at the University of Gothenburg and the University of Copenhagen assessed the available evidence.
Animal studies show that GLP-1 drugs can affect memory and learning, but findings in humans have been mixed. Studies of patient records have linked GLP-1 treatment to a lower risk of dementia in people with type 2 diabetes, although they cannot establish whether the drugs themselves account for the difference.
In Novo Nordisk's clinical trials EVOKE and EVOKE+, semaglutide did not slow disease progression in patients with early Alzheimer's disease, despite changes in several biological markers of the disease.
These results do not rule out the possibility that the drugs could protect brain function in other patients. People with obesity or type 2 diabetes may experience difficulties with attention, planning and processing speed. These problems are often linked to metabolic and vascular health and may therefore respond better to treatment.
Stina Börchers is the first author of the review and a researcher affiliated with the University of Gothenburg and the University of Copenhagen. "We need to find out whether these treatments can help people with obesity or diabetes preserve their cognitive abilities, particularly if treatment begins before cognitive problems become established. It is also important to identify which patients might benefit," says Börchers.
The researchers want to understand whether the drugs' potential effects on the brain result from improved metabolism, direct effects on the brain or a combination of both.
Christoffer Clemmensen is the senior author of the review and a research group leader at the University of Copenhagen. "Obesity medicines are becoming increasingly sophisticated, offering new opportunities to understand how metabolic regulation influences brain function. By disentangling the direct and indirect effects of these drugs on the brain, we may ultimately be able to develop treatments specifically aimed at preserving cognitive function," he says.
The researchers are calling for clinical trials that track memory and other cognitive abilities from the start of treatment. They also emphasize the importance of monitoring older and frail patients, for whom rapid weight loss and loss of muscle mass could impair physical function and reduce the potential benefits of treatment.
Publication details
Stina Börchers et al., Obesity pharmacotherapies and cognition, Science (2026). DOI: 10.1126/science.aek9987
Journal information: Science
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Obesity drugs could lead to new ways to protect the brain (2026, November 6) retrieved 6 November 2026 from https://medicalxpress.com/news/2026-11-obesity-drugs-ways-brain.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com